Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

49.92
+0.91001.86%
Post-market: 49.920.00000.00%19:30 EDT
Volume:463.89K
Turnover:23.17M
Market Cap:3.56B
PE:-16.04
High:51.02
Open:49.65
Low:49.37
Close:49.01
52wk High:94.90
52wk Low:18.26
Shares:71.31M
Float Shares:54.64M
Volume Ratio:0.55
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:2.63
PE(LYR):-20.93

Loading ...

Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating

TIPRANKS
·
Mar 10

Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 10

FACTBOX-Top pharma companies racing to launch a weight-loss pill

Reuters
·
Mar 06

A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment

Simply Wall St.
·
Mar 03

Stifel Nicolaus Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Feb 28

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Feb 27

Did New Shelf Registration and Oral GLP-1 Progress Just Shift Structure Therapeutics' (GPCR) Investment Narrative?

Simply Wall St.
·
Feb 27

Analysts’ Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Alpha Teknova (TKNO)

TIPRANKS
·
Feb 27

Structure Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Structure Therapeutics posts Q4 net income of USD 33.0 million as Q4 R&D expenses rise 105.1% to USD 68.7 million

Reuters
·
Feb 27

BRIEF-Structure Therapeutics Inc. FY Net Income USD -141.202 Million

Reuters
·
Feb 27

Structure Therapeutics Inc. FY Income From Operations USD -176.56 Million

THOMSON REUTERS
·
Feb 27

Structure Therapeutics: Cash, Cash Equivalents of $1.4 Bln as of Dec 31, 2025, Expected to Provide Cash Runway Through End of 2028

THOMSON REUTERS
·
Feb 27